癌症客置化醫療市場：2008年 是由出版商Select Biosciences, Ltd.在2008年07月所出版的。
這份英文市場調查報告書包含166 pages 價格從美金4140起跳。
本報告書內容包括：癌症客置化醫療市場概要、目前的癌症診斷測試及新開發動向、主要產品概要等調查分析、2011年之前的產業收益預測、對MicroRNA及超基因學市場的影響、RNAi治療動向、主要企業介紹等。內容綱要摘記如下：
第1章 市場概要
- 癌症症分子診斷
- 測試類型別市場詳細介紹及個別的價値
- 透過客置化醫療促進癌症治療的決策
- 商業化矩陣
- 報酬不均衡、等
第2章 針對客置化醫療的癌症新生物標記：MicroRNA・超基因學
- MicroRNA・超基因學的潛在角色
- MicroRNA癌症地圖
- MicroRNA與人類的癌症
- 操控癌症相關基因的MicroRNA
- MicroRNA診斷對各疾病領域的影響
- Rosetta Genomics公司利用MicroRNA的癌症診斷
- 主要企業的開發動向
第3章 癌症的RNAi治療環境
第4章 市場分析：癌症客置化醫療
- 癌症客置化醫療的重要性
- 癌症客置化醫療：抗癌藥劑及pharmacodiagnostic檢查併用
- 癌症客置化醫療經濟
- 乳癌臨床醫療的多重基因預測因素
- 各種檢查成本比較
- 其他癌症客置化醫療
- 客置化抗凝血藥療法、等
第5章 客置化醫療相關企業
附錄
Abstract
This is the latest most up-to-date Cancer Personalized Medicine Market Report
from Select Biosciences. This report presents an up-to-date and thorough
analysis of the Cancer Personalized Medicine Marketplace based upon Select
Biosciences continuing industry coverage. Personalized Medicine, especially as
it relates to Cancer, is undergoing significant growth and this report focuses
in on the science, market/commercialization, and diagnostic/therapeutics
trends in this space.
The Cancer Personalized Medicine marketplace represents the paradigm for
personalized medicine market evolution and Select Biosciences focuses in this
report on the various commercialized cancer predictor tests, their current
status, traction in the marketplace, quantitative market opportunities, and
the factors that are driving as well as challenging the expansion of this
space.
Emerging classes of cancer biomarkers such as microRNAs and epigenetics are
also examined in this report as well as the pipeline of RNAi-therapeutics for
cancer. These biomarkers and treatment methodologies are drivers of the growth
of the cancer personalized medicine marketplace for the future and therefore
Select Biosciences provides coverage of these areas in this report-together
with market participants making an impact in these particular areas.
Personalized Medicine marketplace is part of Select Biosciences continuous
industry tracking and as part of this coverage; this report presents
comprehensively the cancer personalized medicine market landscape in terms
of:
- Cancer Diagnostic Tests on the marketplace and in development that are
developed as companion-diagnostics [coupled with a therapeutic regimen]
- Landscape of In Vitro Diagnostic Multivariate Index Assays
[IVDMIAs]-multigene predictors with prognostic/predictive value
- Key Personalized Medicine Products in the Breast Cancer, Colon Cancer,
etc. market spaces-together with the characteristics/features of These
Products-HER2, oncotype DX™, MammaPrint®, UGT1A1, K-RAS, EGFR, etc.
- Worldwide market survey completed recently-June 2008-of qualitative and
quantitative market trends/metrics in this space. Report purchasers receive
access to all the raw data from the market survey via access to secure server
from Select Biosciences as well as all the annotated/analyzed data in the
report. This highly valuable and recently collected dataset is based on an
extensive market analysis performed by Select Biosciences Industry Analyst
Team-all the raw data and analyses based on the data are presented in the
report
- Quantitative market forecast-for the year 2008 through 2011
- Comprehensive profiles of the various market participants in this space
- All report purchasers are entitled to 1 hour of free consultation with
Select Biosciences Industry Analysts
Select Biosciences also includes in this report an overview of the drug
metabolism and toxicity process, the role of specific cytochr ome P450
(CYP450) enzymes, and how these impact personalized medicine.
Furthermore, in this report are presented an overview of the FDA-regulatory
process on In Vitro Diagnostic Multivariate Index Assays (IVDMIAs), and how
this impacts the market acceptance of the various cancer personalized medicine
tests either in development or out in the market.
Table of Contents
Chapter I . Executive Overview of the Space
- Molecular Diagnostics in Cancer: Breakout of the Market By Types of Tests
and Their Value Proposition
- Prognostic vs. Predictive Markers for Cancer
- Personalized Medicine is Driving Cancer Treatment Decisions TODAY
- Commercialization Metrics: Drugs vs. Diagnostics
- The Lopsided Remuneration for Diagnostics: Personalized Medicine is
Changing This Paradigm
- Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for
Personalized Medicine and Drivers for Market Acceptance
- Trajectory of Genomics-based Cancer Biomarker Tests, such as IVDMIAs, for
Personalized Medicine: Drivers and Challenges
- Quantitative Market Metrics: Market Sizes
- The Future of Cancer Personalized Medicine
Chapter II . Emerging Cancer Biomarkers for Personalized Medicine: microRNA-based, Epigenetics-based
- Potential Role of microRNAs and Epigenetics in Cancer Personalized
Medicine-The Potential Market Opportunities
- A microRNA Cancer Map
- microRNAs that are Associated with Human Cancers
- microRNAs that may Regulate Cancer-related Genes - I Particular microRNAs
may regulate specific cancer genes & their effect on cell function
- microRNAs that may Regulate Cancer-related Genes - II. Alteration of
microRNA expression in human malignancies
- Epigenetic Alterations in Cancer
- Predicted Impact of microRNA Diagnostics on Various Disease Areas and
Associated Timelines
- Predicted Impact of microRNA Therapeutics on Various Disease Areas and
Associated Timelines
- Rosetta Genomics Ltd., A Pioneer in Developing and Commercializing
microRNA-based Cancer Diagnostics
- Selected Market Participants Developing Epigenetics-based Cancer
Personalized Tests
Chapter III . RNAi Therapeutics Landscape for Cancer 32-37
Chapter IV. Market Analysis: Cancer Personalized Medicine
- Why Cancer Personalized Medicine? Value Delivered by the Diagnostic and
Associated Value by the Therapeutic
- Cancer Personalized Medicine: Anticancer drugs that can be used together
with a pharmacodiagnostic test
- Economics of Cancer Personalized Medicine
- Multigene Predictors of Clinical Outcome for Breast Cancer
- Comparison of Cost of Tests Across the Market Landscape for Breast Cancer
Testing
- Personalized Medicine in Other Cancers-A Complete Analysis of the Entire
Landscape
- Personalized Warfarin Therapy: Another Paradigm for the Personalized
Medicine Marketplace
- Cancer Personalized Medicine Worldwide Market Survey Data
Chapter V. Industry Participants in Personalized Medicine
- Abbott Molecular
- Affymetrix
- Agendia BV
- Celera
- Cepheid
- Clinical Data: PGXHealth, Cogenics, and Epidauros
- Dako Denmark A/S
- deCODE genetics
- DNA Direct
- DxS Ltd.
- Exact Sciences
- eXagen Diagnostics
- Gen-Probe
- Genelex
- Genentech
- Genomic Health
- Genzyme Genetics
- Illumina
- Luminex
- Monogram Biosciences
- Myriad Genetics
- Nanogen
- Osmetech Molecular Diagnostics
- Perlegen Sciences
- PGxI Laboratories
- Prometheus Laboratories
- Roche Diagnostics
- Siemens Medical Solutions Diagnostics
- Target Discovery
- Third Wave Technologies
- XDx
- Ventana Medical Systems/Roche
Appendix I . Research Methodology
Appendix II . Drug Metabolism Drives Drug Efficacy/ Toxicity
Appendix III . Regulatory Guidelines in Personalized Medicine
